Overview of existing therapies

Targeted Therapies in Oncology

Volumn , Issue , 2007, Pages 1-18

  Giaccone, Giuseppe ^a   Soria, Jean Charles ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053203432     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (38)

1. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83(11):757-66.
2. Baselga J, Arribas J. Treating cancer's kinase 'addiction'. Nat Med 2004; 10(8):786-7.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14):1031-7.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1):57-70.
5. Adjei AA and Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23(23):5386-403.
6. Susman E. Bevacizumab adds survival benefit in colorectal cancer. Lancet Oncol 2005; 6(3):136.
7. Meyerhardt JA and Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med2005; 352(5):476-87.
8. Brand FX, Ravanel N, Gauchez AS, et al. Prospect for anti-her2 receptor therapy in breast cancer. Anticancer Res 2006; 26(1B):715-22.
9. Anonymous. Erlotinib (Tarceva) for advanced non-small cell lung cancer. Med Lett Drugs Ther 2005; 47(1205):25-6.
10. Baselga J and Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23(11):2445-59.
11. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst2001; 93(14):1062-74.
12. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49(17):4682-9.
13. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353(20):2135-47.
14. Ghobrial IM and Adjei AA. Inhibitors of the ras oncogene as therapeutic targets. Hematol Oncol Clin North Am 2002; 16(5):1065-88.
15. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5):965-72.
16. Sebti SM and Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004; 31(Suppl 1): 28-39.
17. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97(11):3361-9.
18. Schmelzle T and Hall MN. TOR, a central controller of cell growth. Cell 2000; 103(2):253-62.
19. Gutcher I, Webb PR, and Anderson NG. The isoform-specific regulation of apoptosis by protein kinase C. Cell Mol Life Sci 2003; 60(6):1061-70.
20. Monnerat C, Henriksson R, Chevalier T. Le, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004; 15(2):316-23.
21. Yu H and Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 2004; 4(2):97-105.
22. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440):1127-34.
23. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 1996; 6(10):393-7.
24. Carlson BA, Dubay MM, Sausville EA, Brizuela L, and Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56(13):2973-8.
25. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102(1):1-4.
26. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303(5659):844-8.
27. Lambert JD, Meyers RO, Timmermann BN, and Dorr RT. Tetra-O-methylnordihydro-guaiaretic acid inhibits melanoma in vivo. Cancer Lett 2001; 171(1):47-56.
28. Dy GK and Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer 2006; 7(Suppl 4):S145-9.
29. Sandler AB. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions. Oncology (Williston Park) 2006; 20(6):626-8.
30. Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembio-chem 2003; 4(10):963-71.
31. Bozec A, Lassalle S, Gugenheim J, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006; 95(6):722-8.
32. Overall CM and Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94(7):941-6.
33. Dalgarno D, Stehle T, Narula S, et al. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2006; 67(1):46-57.
34. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352(11):1092-102.
35. Rajkumar SV, Richardson PG, Hideshima T, and Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23(3):630-9.
36. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23(18):4152-61.
37. Hurtubise A and Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 2006; 58(5):618-25.
38. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5(9):1065-73.